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ABSTRACT 
Parenteral nanoemulsions are regarded as biocompatible drug delivery systems for lypophilic drugs. When it comes to 
delivering actives to the brain as a target site, prolonged circulation time is desirable. The objective of this study was to 
conduct physicochemical characterization of PEGylated nanoemulsions as prospective carriers for enhanced brain 
delivery, using diazepam as a model active substance for brain targeting. Nanoemulsions were prepared by high 
pressure homogenization method and characterized regarding droplet size, zeta potential, pH, conductivity, viscosity 
and in vitro release profile. PEG2000-DSPE and PEG5000-DPPE were used for PEGylation. All the formulations were 
autoclaved and stored at room temperature. After 2 months there were no significant changes in physicochemical 
parameters in autoclaved formulations which rendered them as good potential templates to incorporate drugs for brain 
targeted delivery. 
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INTRODUCTION 
Nanoemulsions are regarded as biocompatible drug 
delivery systems which are especially beneficial for 
parenteral application of water insoluble actives. It is 
considered that the oil droplets are rapidly removed 
from the circulation by the components of the 
mononuclear phagocytic system (MPS) [Hormann, 
2016]. When it comes to brain as a target site, 
prolonged circulation time of oil droplets is beneficial 
as it allows more time for an active to reach and cross 
the blood brain barrier. One of the strategies used to 
prolong the circulation time of parenteral 
nanoemulsions is coating the surface of oil droplets 
with polyethyenglicol (PEG) chains. PEG chains 
provide protection against detections by opsonins from 
plasma and MPS removal from the circulation by 
increasing the surface hydrophilicity [Kandadi, 2011]. 
Diazepam is available on the market as nanoemulsion 
preparation (Diazelmus, Kabi-Pharmacia, Sweden) 
and is commonly used benzodiazepam [Đorđević, 
2013]. The aim of this study was to develop and 
characterize PEGylated parenteral nanoemulsions as 
possible carriers for prospective delivery of actives to 
the brain, using diazepam as a model active substance. 
RESEARCH CONCEPT 
Nanoemulsions (non-PEGylated - NPEG and 
PEGylated) were prepared by high pressure 
homogenization method, autoclaved and characterized 
regarding droplet size, zeta potential, pH and 
conductivity both initially and after 2 months of 
storage at room temperature. Additionally, viscosity 
measurements and in vitro release study of the 
formulations were performed. 
1. Nanoemulsion preparation and sterilization
Diazepam loaded nanoemulsions (2mg/g) were 
prepared using high pressure homogenization method 
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at room temperature. Water and oil phase were 
prepared separately. Aqueous phase (glycerol, 
polysorbate 80, highly purified water and 0,1 M 
NaOH) was added to oil phase (soybean oil, medium 
chain triglycerides, soybean lecithin, 
butylhydroxytoluene and diazepam) and homogenized 
using rotor stator homogenizer (IKA Ultra-Turrax® T25 
digital) at 8000 rpm for 3 minutes. Formulations were 
further homogenized by high-pressure homogenizer 
(EmulsiFlex-C3, Avestin Inc., Canada) for 9 cycles at 
500 bar. PEGylation agents used were PEGylated 
phospholipids: PEG2000-DSPE (P2) or PEG5000-
DPPE (P5), which were added to the aqueous phase at 
concentration of 0,1% or 0,3% (P2_0.1%, P2_0.3% 
P5_0.1%, and P5_0.3%). All formulations were 
sterilized in autoclave at 121°C for 15 minutes. 
2. Size and zeta potential measurements
Formulations were characterized regarding the mean 
droplet size (intensity weighed mean diameter, Z-Ave), 
droplet size distribution - polydispersity index (PDI) 
and zeta potential (ZP) by Zetasizer Nano ZS90 
(Malvern Instruments Ltd., Worcestershire). In order to 
confirm the size measurements and check for larger 
droplets presence laser diffraction measurements were 
performed using Beckman Coulter LS 13 320 
(Beckman Coulter, Inc., Brea, California). 
3. Conductivity, pH and viscosity
Conductivity and pH measurements were performed to 
test the formulations’ stability after sterilization and 
during storage as well as suitability for parenteral 
application. Viscosity measurements were conducted in 
order to assess the formulations’ syringeability and 
suitability for parenteral application. 
4. In vitro release studies
The drug release was studied by dialysis bag method 
using cellulose membrane with molecular weight cut 
off of 12000. Dialysis bags with 2 ml of the 
formulations were placed in 200 ml of the dissolution 
medium - phosphate buffer pH 7,4 (USP) : methanol = 
80:20 (v/v %). Samples were drown after 0.083, 0.167, 
0.333, 0.67, 1, 2, 4, 8, 12 and 24 hours and analyzed 
for diazepam content by spectrophotometer at 230 nm. 
The release profiles were analyzed with different 
kinetic models: zero order, first order, Higuchi, Baker-
Lonsdale, Korsmeyer-Peppas and Hixon-Crowel 
models (DDSolver packet for Microsoft Excel 
apication). 
RESULTS 
The size measurements preformed initially and after 2 
months of storage showed that Z-ave was in the range 
of 180 nm to 220 nm, with PDI below 0,2 for both non-
autoclaved and autoclaved samples (Figure 1.). Laser 
diffraction measurements showed that d100 was below 1 
µm for all samples.  
 
 
Figure 1. Z-ave and PDI results of the non-autoclaved 
formulations 
Zeta potential for all the samples was between -30 and 
-50 mV (Figure 2). Non-autoclaved samples had
significant changes in pH (decreasing from around 7 to
about 5 within 2 months) and conductivity (increasing
from around 100 µS/cm to around 400 µS/cm). As for
the autoclaved samples, pH and conductivity remained
stable at around 7 and 100 µS/cm, respectively.
Viscosity was around 5 mPa*s for all samples.
 
 
Figure 2. Zeta potential for the non-autoclaved 
formulations. 
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The results from in vitro release study are shown on 
Figure 3. 
 
 
Figure 3. In vitro release study – cumulative drug 
release 
DISCUSSION 
All the PEGylated formulations had higher droplet size 
comparing to the non-PEGylated formulation and Z-
ave increased with increasing concentration of 
PEGylated phospholipids. Droplet size was higher 
when using PEG5000-DPPE compared to PEG2000-
DSPE, which can be explained with the longer of PEG 
chains in PEG5000-DPPE formulations. Nevertheless, 
the Z-ave was below 500 nm for all the formulations, 
with no droplets larger than 1 µm detected, which is 
concordant with USP requirements. PDI remained 
below 0.2 showing narrow size distribution. Given that 
the formulations are stabilized with soybean lecithin, 
zeta potential values at around -40 mV were expected. 
During storage and autoclaving phospholipids and oils 
can succumb to hydrolysis, which in turn leads to 
increased negative zeta potential value. This could be 
perceived as beneficial given that the higher zeta 
potential values indicate better stability, but in this case 
it is a consequence of free fatty acid liberation, which 
leads to pH value decrease, which in turn promotes 
further degradation and destabilization in 
nanoemulsions [Klang, 2011]. Interestingly, in 
obtained autoclaved nanoemulsions showed better 
stability in terms of maintaining pH and conductivity 
values compared to the unsterilized formulations, 
which requires further insight . Lower absolute zeta 
potential values can been detected in formulations 
containing PEG5000-DPPE versus the non-PEGylated 
and the formulations containing PEG2000-DSPE, 
probably due to longer PEG chains increasing 
hydrophilicity on the surface. [Kandadi, 2011]. 
Interestingly, it appeared that the autoclaved samples 
showed better stability compared to the non-autoclaved 
samples regarding pH and conductivity measurements. 
Low viscosity of the formulations rendered them safe 
for parenteral use and showed that adding PEGylated 
phospholipids did not significantly increase the 
formulations’ viscosity. 
In the in vitro release study it could be observed that 
the highest release of diazepam was from the non-
PEGylated formulation (Figure 3). That release profile 
was similar with the formulation containing 0,1 % 
PEG2000-DSPE, suggesting that the used 
concentration was too low to coat the nanoemulsion 
droplet surface and slow down the release. The slowest 
release was observed when using 0,3 % PEG2000-
DSPE compared to both the non-PEGylated 
formulation and the formulations containing PEG5000-
DPPE, which could be explained by PEG2000-DSPE 
forming more rigid packing at the interface comparing 
to DPPE chains, therefore causing slower release of the 
incorporated diazepam. This was corroborated by the 
fact that the Higuchi model, which describes drug 
release as a diffusion based process founded in the 
Fick’s law was the best fit to describe the profiles 
(highest R2, Radj
2 and the lowest AIC - Akaike
Information Criterion) [Costa, 2001]. Higuchi 
dissolution constants were lower for the formulations 
containing PEGylated phospholipids which indicated 
that they slow down the diffusion of the diazepam from 
the droplets. 
CONCLUSIONS 
Initial physicochemical characterization suggested that 
investigated nanoemulsions were appropriate for 
parenteral application. Release profiles showed that the 
PEGylated formulations could delay the release of the 
incorporated drugs, which could be beneficial when 
prolonged release of the active is required. They could 
be considered as prospective template carriers for the 
water insoluble actives when prolonged circulation 
time is desired, for example for brain targeted delivery. 
However, further investigations are necessary in order 
to prove pharmacokinetic advantages in vivo, like 
pharmacokinetic study in animal models. 
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